AI-generated summary
This commentary aims to clarify how photobiomodulation therapy should be set up for oral mucositis. The authors suggest a dose range that they say balances efficacy data with current understanding of safety. They also briefly review the molecular basis of photobiomodulation and its controversial link to malignant transformation.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract describes a commentary, so it does not report a new study or patient outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis, Photobiomodulation therapy, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.